Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
For better result, minimum character length is four(4)
CBT 200 Gains 14 Points. More details...
Texas Jury Awards Plaintiff $253 Million. More details...
CBT 200 Manages an 11 Point Gain. More details...
Extended Release Drug Posts Positive Phase II Data. More...
Company Strapped For Cash. More details...
CBT 200 Takes A Small Loss. More details...
CBT 200 Adds on 64 Points or 1.7%. More details...
Potential Blockbusters Come With Side Effects. More...
CBT 200 Scores Another New High. More details...
CBT 200 Slightly Lower. More details...
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China
